HOUSTON--(BUSINESS WIRE)--SpinalCyte, LLC, a spinal technology company focused on autologous regrowth of the spinal disc nucleus using human dermal fibroblasts, announced today the issuance of U.S. Patent No. 8,728,495, “Methods and Compositions For Repair Of Cartilage Using An In Vivo Bioreactor”. The technology described in the patent involves seeding autologous dermal fibroblasts into the nucleus of the spinal disc. The cells, when exposed to in vivo mechanical stress in a low oxygen environment, will then differentiate into chondrocytes to regrow the nucleus of the spinal disc. The claims also cover an absorbable scaffolding to direct the mechanical stress into the seeded cells.
Help employers find you! Check out all the jobs and post your resume.
